P08.01â Low-dose checkpoint inhibitors with hyperthermia and IL-2 are safe and effective in stage IV cancer with unfavorable immunological profile (MSI low , PD-L1 under 1%, TMB low ) â A single-institution experience from 2015 to 2020
Kleef, R, Nagy, R, Bacher, V, Bakacs, T, Lausch, T, McKee, D, Moss, R, Bojar, H, Thoennissen, NVolume:
8
Journal:
Journal for ImmunoTherapy of Cancer
DOI:
10.1136/jitc-2020-itoc7.97
Date:
October, 2020
File:
PDF, 80 KB
2020